导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.18% | 1721/4773 |
| 近一周 | -2.18% | 1411/5462 |
| 近一月 | 1.24% | 397/5421 |
| 近一季 | -0.34% | 814/5209 |
| 近半年 | -2.72% | 1996/4920 |
| 近一年 | -1.79% | 2923/4366 |
| 近两年 | 38.33% | 1970/2954 |
| 近三年 | 43.11% | 655/2253 |
| 成立以来 | 27.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.41% 732/4961 |
-11.02% 4227/5312 |
- - |
- - |
| 2025 | 15.61% 2526/4813 |
0.68% 1795/3635 |
11.36% 189/4076 |
3.13% 3769/4524 |
-0.01% 2299/4813 |
| 2024 | 24.27% 295/3463 |
0.93% 920/2808 |
16.34% 4/3014 |
4.08% 2906/3129 |
1.67% 1041/3463 |
| 2023 | 4.43% 229/2656 |
5.05% 837/2280 |
1.29% 224/2385 |
0.17% 382/2515 |
-2.03% 410/2655 |
| 2022 | -0.71% 42/2207 |
3.16% 46/1919 |
1.51% 1465/2016 |
-14.73% 1139/2113 |
11.20% 150/2208 |
| 2021 | -2.15% 837/1822 |
11.78% 22/1255 |
-2.61% 1220/1330 |
-1.55% 530/1466 |
-8.70% 1589/1822 |
| 2020 | -14.80% 999/1250 |
-16.31% 995/1028 |
3.05% 952/1067 |
-4.63% 1108/1164 |
3.59% 903/1184 |
| 2019 | 13.62% 704/1092 |
12.52% 707/754 |
-4.17% 421/804 |
-8.36% 827/850 |
14.99% 19/918 |
| 2018 | -14.14% 95/834 |
- - |
- - |
- - |
-5.54% 36/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证港股通高股息投资ETF联接(LOF)C VS. 长安沪深300非周期A(740101) |